Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is positioning to capitalize on potential changes in U.S. peptide regulations that could expand access through specialty pharmacies and telehealth platforms. As the FDA considers allowing additional peptides for pharmacy compounding, the company plans to differentiate itself by developing proprietary peptide formulations and delivery technologies designed to improve stability, absorption, administration and performance. Adaptogenics has also acquired nutritional research assets from Berkwood Research to support a GLP-1 companion initiative focused on preserving muscle mass, strength and metabolic health during medically induced weight loss. Recent leadership additions, including healthcare dealmaking executive Antoun Nabhan as president and Dr. Robert Bergia as a scientific advisor, are expected to support research, licensing, acquisitions and strategic partnerships.
To view the full article, visit https://nnw.fm/QhT32
NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://nnw.fm/ADPT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer